Exciting BS3 Growth Update
We are thrilled to share that due to continued strong growth in demand, BS3 is embarking on the next phase of expansion and proudly announce the launch of our next state-of-the-art pharmaceutical Schedule 8/9 vault. This new vault not only expands our storage capabilities but also enhances the security and protection of your valuable assets. As a company dedicated to delivering the highest standards of service, we recognize the need for specialised storage solutions. Our Pharmaceutical Schedule 8/9 Vault has been designed with cutting-edge security features and advanced technology.
Understanding the upcoming changes to MDMA & Psilocybin access
3rd February 2023, the Therapeutic Goods Administration (TGA) announced that from the 1st July 2023, medical use of MDMA and Psilocybin will be rescheduled from Schedule 9 (prohibited substances) to Schedule 8 (controlled medicines) of the Poisons Standard. Which will enable authorised psychiatrists to prescribe these substances for treatment-resistant depression and treatment resistant post-traumatic stress disorder.
Global pharmaceutical majors agree to work together to hit carbon emission goals
With the pharmaceutical industry contributing as much as 4-5% of global carbon emissions, it's great to see some of the leaders in the industry doing their part. Seven of the biggest have teamed up to pledge to work together to reduce carbon emissions in supply chains, health-care delivery and clinical trials. A joint effort that will enable the industry to achieve far more toward reducing industry emissions than individual companies could alone.
